@FierceMedDev: Abbott gets EU go-ahead for implant in aging eyes. More | Follow @FierceMedDev
@StacyALawrence: Study: 3D mammograms improve breast cancer detection. Story | Follow @StacyALawrence
@MichaelGFierce: Sinus drug delivery startup Intersect ENT files for $80 million IPO. News via the Silicon Valley Business Journal | Follow @MichaelGFierce
@EmilyWFierce: Hospital networks leaking data through misconfigured SMB service, leaving devices open to attack. Story from Wired | Follow @EmilyWFierce
> Healthcare logistics company, Owens & Minor ($OMI) snagged a $208 million acquisition of Medical Action Industries ($MDCI). OMI hopes the new addition of the custom procedure trays (CPTs) and minor procedure kits producing MDCI will broaden their ability to reach a wide range of patients. Release
> Paralyzed Ohio man moves his hand with his own thoughts for the first time since his accident four years ago, thanks to Neurobridge technology created by The Ohio State Wexner Medical Center and Battelle. The technology reconnects the brain to muscles using electronic neural bypass tools that allow patients with spinal cord injuries to regain control. Story
> Signal Genetics ($SGNL) is closing its IPO of $10 per share after grossing $8.5 million. Release
> Smith & Nephew ($SNN) halted U.S. sales of its RENASYS Negative Pressure Wound Therapy product after FDA demanded the company apply for a new regulatory clearance so the administration can reevaluate additions to the therapy line. Release
Biotech News
@FierceBiotech: AbbVie makes its pitch for Shire buyout, U.K. tax gambit. More | Follow @FierceBiotech
@JohnCFierce: Talking to Shanghai-based biotech exec, going to do PhI in Australia because of better rep, faster regulatory decision on IND--says something. | Follow @JohnCFierce
@DamianFierce: J&J biz cards creating a sub-market at #BIO2014. Will trade for a Stoffels rookie card or hologram edition Gorsky. Picture | Follow @DamianFierce
@EmilyMFierce: Diagnostics maker Cepheid partners with AstraZeneca, Glaxo to combat antibiotic resistance. News | Follow @EmilyMFierce
> Affymax, once a promising biotech, is dissolving. Item
> FDA bars Basilea antibiotic from U.S. market, demands new PhIII data. More
> Versant's Inception plants its booming biotech startup model in Montreal. Story
Pharma News
@FiercePharma: Prime time for reaching smartphone users? When they're waiting on a doc. More | Follow @FiercePharma
@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story from FierceBiotech | Follow @TracyStaton
@EricPFierce: Government won't let Indian drugmakers dump price capped 'essential drugs' if they control 1% of the market. Article | Follow @EricPFierce
@CarlyHFierce: Alere rethinks BBI IPO. Story via FierceDiagnostics | Follow @CarlyHFierce
> AbbVie can argue for a Shire buy, but price is the thing--and $51B might do it. News
> Novo Nordisk exec: We'll double sales within 10 years. More
> GSK expects to meet flu vaccine demand but even short interruptions can be costly. Story
> J&J, GSK meds join Sovaldi, Tecfidera in blockbuster-to-be crowd. Item
Drug Delivery News
> Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. More
> InVivo Therapeutics to ax hydrogel drug delivery program, cutting jobs. Story
> Self-healing hydrogel and ultrasound combo allows for 'on demand' delivery. Article
> FDA issues guidances on development of nanotechnology products. Report
> Microneedle patch reduces scar tissue in Singapore studies. Item
> Transdemeral delivery patchmaker Zosano to debut on Nasdaq. News
Diagnostics News
> Qiagen wins FDA OK for organ transplant test. More
> Roche lends Dx tech to Ferring for an infertility treatment. Article
> Cepheid partners with AstraZeneca, Glaxo on drug-resistant infections. News
> Definiens bags $20.4M for tissue diagnostics. Report
> Enzo scores $7M in patent battle with PerkinElmer. Item
> Alere rethinks BBI IPO. Story
Pharma Marketing News
> Novo Nordisk can double sales in a decade, deputy CEO says. Item
> Bring out the confetti: 7 of 2013's launches will join Sovaldi, Tecfidera in blockbuster land. Story
> Prime time for reaching smartphone users? When they're waiting on a doc. More
> FDA's social media translation for brand managers: Don't use Twitter. Article
> Can clot-fighters get a boost from the U.K.'s new enthusiasm? Report
> Amarin picks up Pawn Stars host to pitch its struggling fish-oil pill, Vascepa. News